Latest news with #Permethrin
Tom's Guide
22-05-2025
- Lifestyle
- Tom's Guide
I'm a sleep writer — 3 products I'd buy to bed bug proof my mattress in the Memorial Day sales
It's officially bed bug season. The hot weather and the increase in travel over the summer is a recipe for infestations, with bed bugs feeding and breeding quicker than ever. So, what steps can you take to prevent these pests from taking over your bed? Once bed bugs enter your mattress, it's a tricky job trying to get rid of them, let alone stopping them from spreading through the rest of your home. If you've invested in one of this year's best mattresses, you'll want to protect it from creepy crawlies, not only for your sleep hygiene, but also for your sleep quality. And the good news is that you can. With these three products, currently discounted in the Memorial Day mattress sales, you can reduce the risk of bed bugs settling in your mattress, keeping your sleep environment fresh, clean and pest free. While the best mattress protectors do a great job at protecting your bed from spills, stains and accidents, they won't do much against an infestation of bed bugs. This is because they only cover the top of your mattress, and often, these pests will crawl into your mattress from underneath. The solution? A mattress encasement. These cover the whole mattress and zip up at the edge, stopping anything from reaching your bed. Opt for a breathable fabric so you don't trap heat and impact the temperature regulation of your mattress. Alternatively, anti-bed bug mattress liners are an effective solution. These are essentially fitted sheets that can stop bed bugs from feeding and breeding, which means they die within just 10 minutes of contact with the liner. Linenspa Zipped Mattress Encasement: was from $19.99 from $17.59 at AmazonNot only is this encasement waterproof, but it's also made from ultra-thin, flexible fabric to keep your bed breathable. It can fit over up to 12' mattresses, and it zips up at the foot of the bed to protect from bed bugs, dust mites and other allergens. The fabric is hypoallergenic, helping you keep a clean sleep environment, and is OEKO-Tex Standard 100 certified, meaning it has been tested and cleared for any toxic materials. Currently a queen is $21.99 (was $24.99) on Amazon, and you can request the 10-year manufacturer warranty. ActiveGuard Mattress Liner: from $61.20 at AmazonThe ActiveGuard Mattress Liner is an EPA-registered bed bug product intended to 'kill bed bugs and dust mites in mattresses and box springs.' The liner fits over your bed like a normal fitted sheet, but the hypoallergenic material is treated with Permethrin which kills bed bugs. A queen is currently $81.90 on Amazon. While a vacuum alone is unlikely to kill an infestation, it's an important bed bug prevention step. Regularly vacuuming your mattress can help reduce the build up of dust mites and other allergens, and keep a clean and hygienic sleep environment. Bed bugs are attracted to human odor and warmth and clutter creates an ideal environment for them to thrive, so keeping a tidy bedroom will help deter pests from settling in your mattress. On top of this, regularly vacuuming your mattress will get rid of any existing bed bugs or bed bug eggs, helping you spot the early signs of an infestation and taking steps to prevent it. Jigoo Mattress Vacuum Cleaner: was $169.99 now $126.99 at AmazonThis powerful vacuum cleaner has a UV light technology built in to kill dust mites and other allergens. On top of this, it's heated air maintains a 140°F temperature, which kills bacteria, and is hot enough to kill bed bugs and their eggs. You'll be able to watch the digital screen as you vacuum which shows a real-time cleanliness index so you can ensure every inch of your bed is clean. Right now, it's discounted to $126.99 (was $169.99) on Amazon. While no mattress can prevent bed bugs alone, you can keep a super fresh and clean bed set up by investing in an anti-allergen mattress. These are beds that have a hypoallergenic cover or use hypoallergenic materials which help to prevent dust mites, pollen, pet dander, dead skin and more from accumulating and building up in your bed. While it won't stop bed bugs, it'll help you maintain a clean environment that will naturally deter them. Birch Natural mattress: was from $1,373.33 now from $1,030 at BirchThe best organic mattresses often incorporate hypoallergenic natural latex instead of synthetic materials like memory foam, and the Birch Natural mattress is a great example of this. Made from layers of organic wool, latex and cotton, the mattress is breathable and moisture wicking, as well as naturally repellant to allergens. Read our full Birch Natural mattress review to see if it's the right choice for you. A queen is currently discounted for Memorial Day to $1,399 (was $1,865.33), and you'll get a 100-night trial, a limited lifetime warranty and fast free shipping.
The Market Online
29-04-2025
- Business
- The Market Online
Cipher Pharmaceuticals' Natroba granted Medicaid preferred status in Illinois
Cipher Pharmaceuticals (TSX:CPH), a profitable specialty pharma company, reports that its Natroba treatment for scabies and head lice has been upgraded to preferred status by the state of Illinois Concurrently, the state has downgraded Natroba's main competitor, Permethrin 5%, to non-preferred status Cipher is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology Cipher Pharmaceuticals stock has added 50.23 per cent year-over-year and 1,322.22 per cent since 2020 Cipher Pharmaceuticals (TSX:CPH), a profitable specialty pharma company, reports that its Natroba treatment for scabies and head lice has been upgraded to preferred status by the state of Illinois. Concurrently, the state has downgraded Natroba's main competitor, Permethrin 5%, to non-preferred status. According to Tuesday's news release, the changes mean that 'all Medicaid treatments for scabies and Permethrin 5% prescriptions in the state must first step through Natroba being the preferred treatment in Illinois.' The company believes that recent studies showing parasitic resistance to Permethrin played a determining factor in the updated preferred drug listing. See work by Rinaldi and Simonart for further reference. Cipher has delivered positive net income over the past five fiscal years, with a high of US$26.64 million in 2022, and grew revenue by 58 per cent in 2024 thanks to increasing market share and the acquisition of Natroba. Investors have collected an over 1,300 per cent return since 2020. Leadership insights 'The medical decision made by the state of Illinois is just another example of the effectiveness of Natroba (Spinosad) and what clear growth potential for the product remains ahead of us,' Craig Mull, Cipher Pharmaceuticals' interim chief executive officer, said in a statement. 'We believe it is only a matter of time until more state pharmacy directors require step-through of Natroba representing the standard of care in the treatment of scabies and head lice. We are in active discussions with other U.S. states to build upon this recent success, and we continue to believe there is significant potential outside the U.S. to out-license Natroba whereby lice resistance to Permethrin-based products is a pervasive worldwide issue and whereby Natroba fills an unmet need.' About Cipher Pharmaceuticals Cipher is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The company markets its products in Canada, South America and the United States. Cipher Pharmaceuticals stock (TSX:CPH) is up by 3.31 per cent on the news trading at C$12.80 as of 10:01 am. The stock has added 50.23 per cent year-over-year and 1,322.22 per cent since 2020. Join the discussion: Find out what everybody's saying about this pharmaceuticals stock on the Cipher Pharmaceuticals Inc. Bullboard and check out Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here. (Top photo: Cipher Pharmaceuticals)
Cision Canada
29-04-2025
- Business
- Cision Canada
Cipher Pharmaceuticals Secures Medicaid Step-Through Preferred Status for Natroba™ in the state of Illinois
MISSISSAUGA, ON, April 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher" or the " Company") proudly announces the state of Illinois has updated its Preferred Drug Listing ("PDL") where Cipher's product Natroba™, for the treatment of scabies and head lice, has obtained preferred drug status on Medicaid state plans, and whereby its main competitive product Permethrin 5% has been downgraded to non-preferred status. As a result of this change, all Medicaid treatments for scabies and Permethrin 5% prescriptions in the state must first step through Natroba™ being the preferred treatment in Illinois. Cipher's management team worked diligently with Illinois state pharmacy directors who made their clinical choice and prefer Natroba as the standard of care in the treatment of scabies and head lice. Studies have shown parasites have developed resistance to Permethrin based products which are no longer effective, and whereby Cipher believes this was a key factor in the decision made by the state of Illinois. Medicaid PDLs typically influence the prescribing habits of physicians as they generally represent the most restrictive formulary plans. Cipher believes that changes to Medicaid PDLs, such as the recent change in Illinois, will influence prescribing habits of physicians for commercial patients and other payor plans. Craig Mull, Interim CEO commented: "The medical decision made by the state of Illinois is just another example of the effectiveness of Natroba™ (Spinosad) and what clear growth potential for the product remains ahead of us. We believe it is only a matter of time until more state pharmacy directors require step-through of Natroba™ representing the standard of care in the treatment of scabies and head lice. We are in active discussions with other U.S. states to build upon this recent success, and we continue to believe there is significant potential outside the U.S. to out-license Natroba™ whereby lice resistance to Permethrin based products is a pervasive worldwide issue and whereby Natroba fills an unmet need." About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit Forward-Looking Statements This document includes forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among others, statements with respect to the state of Illinois Preferred Drug Listing updates, the potential impact on the Company, the Company's expectations for Natroba™ and the Company's plans for Natroba™, our objectives and goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates and intentions. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. By their nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, our ability to enter into development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on a limited number of products; our dependency on protection from patents that will expire; the extent and impact of health pandemic outbreaks on our business; integration difficulties and other risks if we acquire or in-license technologies or product candidates; reliance on third parties for the marketing of certain products; the product approval process by regulators which can be highly unpredictable; the timing of completion of clinical trials, regulatory submissions and regulatory approvals; reliance on third parties to manufacture our products and events outside of our control that could adversely impact the ability of our manufacturing partners to supply products to meet our demands; we may be subject to future product liability claims; unexpected product safety or efficacy concerns may arise; we generate license revenue from a limited number of distribution and supply agreements; the Company's performance depends, in part, on the performance of its distributors and suppliers; the pharmaceutical industry is highly competitive with new competing product entrants; requirements for additional capital to fund future operations; products may be subject to pricing regulation; dependence on key managerial personnel and external collaborators; the ability to receive regulatory approvals for products in development or future products; certain of our products are subject to regulation as controlled substances; limitations on reimbursement in the healthcare industry; the ability to convince public payors and hospitals to include our products on the approved formulary lists; ability to receive timely payment from certain customers; application of various laws pertaining to health care fraud and abuse; the Company's reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the healthcare industry generally; we may be unsuccessful in evaluating material risks involved in completed and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; success in applying tax loss carry forwards; inability to meet covenants under our long-term debt arrangement; compliance with privacy and security regulation; our policies regarding product returns, allowances and chargebacks may reduce revenues; additional regulatory burden and controls over financial reporting; application of regulations that could restrict our activities and abilities to generate revenues as planned; reliance on third parties to perform distribution, logistics, invoicing, regulatory and sales services; general commercial litigation, class actions, other litigation claims and regulatory actions; the difficulty for shareholders to realize in the United States upon judgments of U.S. courts predicated upon civil liability of the Company and its directors and officers who are not residents of the United States; increases in tariffs, trade restrictions or taxes on our products; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent laws; inability to protect our trademarks from infringement; shareholders may be further diluted if we issue securities to raise capital; volatility of our share price; the fact that we have a significant shareholder; our operating results may fluctuate significantly; and our debt obligations will have priority over the common shares of the Company in the event of a liquidation, dissolution or winding up. We caution that the foregoing list of important factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, may be found in the "Risk Factors" section of our MD&A for the year ended December 31, 2024 and the Company's Annual Information Form, and elsewhere in our filings with Canadian securities regulators. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language. SOURCE Cipher Pharmaceuticals Inc.
